z-logo
Premium
An international collaborative study to compare different von Willebrand factor glycoprotein Ib binding activity assays: the COMPASS‐VWF study
Author(s) -
Szederjesi A.,
Baronciani L.,
Budde U.,
Castaman G.,
Lawrie A. S.,
Liu Y.,
Montgomery R.,
Peyvandi F.,
Schneppenheim R.,
Várkonyi A.,
Patzke J.,
Bodó I.
Publication year - 2018
Publication title -
journal of thrombosis and haemostasis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.947
H-Index - 178
eISSN - 1538-7836
pISSN - 1538-7933
DOI - 10.1111/jth.14206
Subject(s) - von willebrand factor , medicine , ristocetin , von willebrand disease , platelet , immunology
Essentials New VWF activity assays are increasingly used but information on their comparability is limited. This is an ISTH SSC‐organized study (expert labs, 5 countries) to compare all available assays. VWF activity by six assays correlated well with each other. The new assays show improved characteristics ‐ minor differences are noted.Summary Background Several new assays have become available to measure von Willebrand factor ( VWF ) activity. The new assays appear to have improved performance characteristics compared with the old reference standard, ristocetin cofactor activity ( VWF : RC o), but information is limited about how they compare with VWF : RC o and each other. Methods The von Willebrand factor Subcommittee of the International Society for Thrombosis and Haemostasis ( ISTH ) Scientific and Standardization Committee ( SSC ) designed a collaborative study involving expert laboratories from several countries to compare available tests with each other and with VWF : RC o. Eight laboratories from five countries were provided with blinded samples from normal healthy individuals and well‐characterized clinical cases. Laboratories measured VWF activity using all tests available to them; data from six laboratories, not affected by thawing during transportation, are included in this study. Results All tests correlated well with VWF : RC o activity ( r ‐values ranged from 0.963 to 0.989). Slightly steeper regression lines for VWF :Ab and VWF : GPI bM were clinically insignificant. The new assays showed improved performance characteristics. Of the commercially available assays, the VWF : GPI bR using the AcuStar system was the most sensitive and could reliably detect VWF activity below 1  IU   dL −1 . The lower limit of the measuring interval for the VWF : GPI bM and the VWF : GPI bR assays was in the 3–4 and 3–6  IU   dL −1 range, respectively. Inter‐laboratory variation was also improved for most new assays. Conclusion All VWF activity assays correlated well with each other and the VWF : RC o assay. The slight differences in characteristics found in the COMPASS ‐ VWF study will assist the VWF community in interpreting and comparing activity results.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here